Oxford Biomedica plc provided earnings guidance for the year ended December 31, 2023 and for the fiscal year 2024. In line with guidance provided at the Interim Results, revenues for the year ended 31 December 2023 are expected to be approximately £90 million.

Projected fiscal year 2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmes.